Related Experiment Video
Updated: Feb 12, 2026

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
Advances on the BRAF Front in Colorectal Cancer
1Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. fjanku@mdanderson.org.
Abstract:
Colorectal cancer with BRAFV600E mutation can be effectively treated with combination approaches involving inhibition of BRAF, MEK, and EGFR proteins. However, activation of the MAPK pathway, often due to emergence of previously undetected molecular alterations, ultimately leads to adaptive therapeutic resistance. Novel combination strategies combining inhibition of BRAF, ERK, and EGFR can be used to prevent MAPK pathway-driven resistance and warrant further investigation. Cancer Discov; 8(4); 389-91. ©2018 AACRSee related article by Corcoran et al., p. 428See related article by Hazar-Rethinam et al., p. 417.
Insights
Targeting BRAF, MEK, and EGFR effectively treats BRAF-mutant colorectal cancer. New strategies inhibiting BRAF, ERK, and EGFR may prevent adaptive resistance to MAPK pathway therapies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Colorectal cancer (CRC) with BRAF V600E mutation presents therapeutic challenges.
- Current combination therapies target BRAF, MEK, and Epidermal Growth Factor Receptor (EGFR).
- Adaptive resistance to MAPK pathway inhibitors often emerges due to new molecular alterations.
Purpose of the Study:
- To investigate novel combination strategies for treating BRAF-mutant colorectal cancer.
- To explore methods for preventing adaptive resistance driven by the MAPK pathway.
- To evaluate the potential of combined BRAF, Extracellular signal-Regulated Kinase (ERK), and EGFR inhibition.
Main Methods:
- Review of current therapeutic strategies for BRAF-mutant CRC.
- Analysis of mechanisms underlying adaptive resistance to MAPK pathway inhibitors.
- Conceptualization of novel combination therapies targeting BRAF, ERK, and EGFR.
Main Results:
- BRAF, MEK, and EGFR inhibition shows efficacy in BRAF-mutant CRC.
- Emergence of new molecular alterations can activate the MAPK pathway, leading to resistance.
- Combined inhibition of BRAF, ERK, and EGFR presents a promising strategy to overcome resistance.
Conclusions:
- BRAF-mutant colorectal cancer treatment can be enhanced by targeting BRAF, MEK, and EGFR.
- Understanding adaptive resistance mechanisms is crucial for developing durable therapies.
- Novel combinations targeting BRAF, ERK, and EGFR warrant further clinical investigation to prevent therapeutic resistance.
Related Concept Videos
Overview of Advanced Functional Groups
Functional groups are groups of atoms with specific chemical properties that occur within organic molecules and are sometimes denoted as “R”. Functional groups can “functionalize” a compound by enabling it to adopt different physical and chemical properties.
Types of Advanced Functional Groups
The table below summarizes some of the major functional groups in organic chemistry.
Extraction: Advanced Methods
Sample Preparation for Analysis: Advanced Techniques
Acid digestion with strong acids is commonly used to dissolve inorganic materials that are insoluble (do not dissolve) in water. This method can be useful for...
Cardiopulmonary Resuscitation V: Advanced Airway Management Techniques
Cancer
What is Cancer?
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...

